Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$78,633.00+7.76%ETH$2,533.09+8.95%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
ZB

NASDAQ · ZBIO

Zenas BioPharma, Inc.

Healthcare · Biotechnology

$31.62

Up+$0.67 (+2.12%)

Updated Aug 21, 2026, 10:51 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.69B
P/E ratio
-9.52
Dividend yield
0.00%
52-week range
$16.41 – $34.05
Volume
1.17M
Avg. volume
419.1K

Price performance

ZBIO price history

1M range · 21 trading sessions · Daily adjusted prices

ZBIO closed at $31.62 after 21 trading sessions, up 2.03% for the selected period.

Last close
$31.62
Period change
+2.03%
Period low
$29.20
Period high
$32.82
Daily close
View OHLC price history
ZBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 20, 2026$30.72$32.20$29.50$31.621.17M
Aug 19, 2026$32.80$32.8899$30.92$31.252.7M
Aug 18, 2026$30.22$31.96$30.22$31.91659.82K
Aug 17, 2026$29.95$30.81$28.72$30.50490.11K
Aug 14, 2026$28.76$30.31$28.163$29.51630.04K
Aug 13, 2026$30.39$31.00$27.81$29.20881.51K
Aug 12, 2026$32.05$32.9734$31.12$31.29461.6K
Aug 11, 2026$31.43$32.88$30.71$32.441.07M
Aug 10, 2026$32.24$32.695$31.605$31.99409.92K
Aug 7, 2026$32.85$33.08$31.65$32.43264.07K
Aug 6, 2026$31.51$33.00$31.32$32.17676.93K
Aug 5, 2026$31.93$32.38$31.23$31.86411.11K
Aug 4, 2026$31.09$31.73$30.4501$31.42378.13K
Aug 3, 2026$32.075$32.18$30.33$31.13429.28K
Jul 31, 2026$32.69$32.95$30.60$31.44452.23K
Jul 30, 2026$31.37$32.96$30.75$32.27738.02K
Jul 29, 2026$32.43$32.43$30.25$31.09625.61K
Jul 28, 2026$32.64$33.30$31.81$32.29773.85K
Jul 27, 2026$30.91$33.42$30.85$32.821.15M
Jul 24, 2026$31.30$31.30$30.09$30.39558.98K
Jul 23, 2026$31.04$31.555$30.30$30.99402.04K

Latest ZBIO news

The latest Smart Investors Daily articles mentioning ZBIO.

Stock researchCompany · Overview

ZBIO research

Overview

Company profile and research snapshot.

Company profile

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$43.33
Implied upside
—
Analysts
—
ZBIO recent ratings
DateFirmRatingTarget
Aug 14, 2026WedbushOutperform—
Aug 14, 2026GuggenheimBuy—
Aug 14, 2026Morgan StanleyEqual-Weight—
May 15, 2026HC Wainwright & Co.Buy—
May 14, 2026Morgan StanleyEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 20, 2026

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on February 17, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 35,

Yahoo · Feb 19, 2026

Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets navigated a quarter supported by optimism about potential monetary easing and caution regarding economic growth and valuations. Early gains were driven by strong AI-related earnings […]

Yahoo · Feb 18, 2026

Why Zenas BioPharma (ZBIO) Is Up 24.6% After Obexelimab’s Phase 2 MS Trial Success - And What's Next

Zenas BioPharma recently reported that its lead candidate obexelimab met the primary endpoint in the Phase 2 MoonStone trial in relapsing multiple sclerosis, with a highly statistically significant reduction in new gadolinium-enhancing T1 lesions and a safety profile consistent with prior studies. The data, presented as a late-breaking oral session at the ACTRIMS Forum 2026 and supported by 24-week durability results, highlight obexelimab’s potential to curb inflammatory brain activity while...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By